The ARTNet Podcast

NCI ARTNet
  • 5.0 (1)
  • Health & Fitness

Why do cancer treatments work for some patients at first, only to stop working later? In the premiere episode of the ARTNet Podcast, we speak with Dr. Jeffrey Tyner from Oregon Health & Science University about the complex biology behind acquired resistance to cancer therapies. Dr. Tyner shares insights into how cancer cells adapt and survive treatment, the critical role of the tumor microenvironment, and why understanding resistance mechanisms is essential for developing more durable therapies. The conversation also explores how collaboration across the ARTNet Consortium is helping researchers connect data, models, and expertise to better understand cancer relapse and treatment failure. From leukemia research to large-scale data sharing, this episode offers an inside look at one of the biggest challenges in modern oncology — and the scientific efforts underway to outsmart cancer before it fights back

Episodes

  1. Why Cancer Fights Back: A Conversation with Jeffrey Tyner

    May 11

    Why Cancer Fights Back: A Conversation with Jeffrey Tyner

    Featuring Jeffrey Tyner Professor, Oregon Health & Science University Principle Investigator, ARTNet AML U54 Center Dr. Tyner is a leading researcher in cancer biology and therapeutic resistance, with a focus on acute myeloid leukemia (AML), functional precision oncology, and mechanisms of acquired resistance to targeted therapies. Hosted by David Goodrich Professor, Roswell Park Comprehensive Cancer Center ARTNet Coordinating and Data Management Center Dr. Goodrich leads discussions exploring the science, collaboration, and translational impact of cancer resistance research across the ARTNet Consortium. Episode Summary The conversation explores the complexity of acquired resistance in cancer therapy, emphasizing the role of cell state and cellular plasticity in driving resistance mechanisms. Dr. Tyner discusses the challenges of studying dynamic resistance processes, the promise of targeting cell state plasticity to overcome therapeutic failure, and how resistance trajectories evolve over time. The discussion also highlights the importance of identifying the optimal window for intervention and the growing role of collaborative science within the ARTNet Consortium in advancing cancer resistance research. Despite the complexity of the problem, the episode reflects a strong sense of optimism about the future of precision oncology and translational cancer research. Key Takeaways Acquired resistance is a dynamic and evolving process in cancer therapyCell state plasticity plays a central role in therapeutic resistanceResistance mechanisms can differ across patients and tumor contextsUnderstanding resistance trajectories may reveal new therapeutic opportunitiesCollaborative research and data sharing are essential for advancing precision oncology Chapters 00:00 Introduction to ARTNet Consortium05:15 From Targeted Therapy to Tumor Complexity10:15 Understanding Acquired Resistance and Tumor Evolution19:50 Cell State Plasticity and Therapeutic Resistance24:05 Resistance Trajectories and Future Treatment Strategies29:00 The Future of Precision Oncology and the Role of ARTNet

    35 min
  • 1 Episode

About

Why do cancer treatments work for some patients at first, only to stop working later? In the premiere episode of the ARTNet Podcast, we speak with Dr. Jeffrey Tyner from Oregon Health & Science University about the complex biology behind acquired resistance to cancer therapies. Dr. Tyner shares insights into how cancer cells adapt and survive treatment, the critical role of the tumor microenvironment, and why understanding resistance mechanisms is essential for developing more durable therapies. The conversation also explores how collaboration across the ARTNet Consortium is helping researchers connect data, models, and expertise to better understand cancer relapse and treatment failure. From leukemia research to large-scale data sharing, this episode offers an inside look at one of the biggest challenges in modern oncology — and the scientific efforts underway to outsmart cancer before it fights back

Information

  • Creator
    NCI ARTNet
  • Episodes
    1
  • Rating
    Clean
  • Copyright
    © 2026 NCI ARTNet